A higher-than-median expression level of SOCS1, SOCS3 or TCEB1 also predicts a poor prognosis for WHO grade-IV glioma patients compared to those with lower-than-median expression (Figure 5). This evidence concerns the gene ELOC and central nervous system cancer.